CRUSH!!MDS 

2014 Clinical Research Consortium American Society of Hematology Abstracts

1. 530 - An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies (Oral Presentation)
   Eric Padron, MD, Guillermo Garcia-Manero, MD, Mrinal M. Patnaik, MBBS, Raphael Itzykson, Terra Lasho, PhD, Aziz Nazha, MD, Raajit K. Rampal, MD, PhD, Matias Eugenio Sanchez, MD, Elias Jabbour, MD, Najla H Al Ali, Zachary Thompson, PhD, Ji-Hyun Lee, PhD, Simona Colla, Pierre Fenaux, MD, PhD, Hagop M. Kantarjian, MD, Sally Killick, Mikkael A. Sekeres, MD, MS, Alan F List, MD, Francesco Onida, MD, Rami S Komrokji, MD, Ayalew Tefferi, MD and Eric Solary
   
   
2. 823 - In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations (Oral Presentation)
   Hideki Makishima, MD, PhD, Kenichi Yoshida, MD, PhD, Thomas LaFramboise, PhD, Bartlomiej P Przychodzen, Matthew Ruffalo, BS, Inés Gómez-Seguí, MD, Yuichi Shiraishi, PhD, Masashi Sanada, MD, PhD, Yasunobu Nagata, MD, PhD, Yusuke Sato, MD, Aiko Sato-Otsubo, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Tsuyoshi Nakamaki, MD, Wolf-Karsten Hofmann, MD, Shuichi Miyawaki, MD, PhD, Shigeru Chiba, MD, PhD, Satoru Miyano, PhD, Holleh Husseinzadeh, MD, Naoko Hosono, MD, PhD, Chantana Polprasert, MD, Bhumika J Patel, MD, Swapna Thota, MD, Brittney Dienes, Kathryn M Guinta, Lee-Yung Shih, MD, Yogen Saunthararajah, MD, Yusuke Okuno, MD, PhD, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD
   
   
3. 1893 - Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events (Poster)
   Bhumika J Patel, MD, Dayong Huang, MD, Swapna Thota, MD, Bartlomiej P Przychodzen, Hirotoshi Sakaguchi, MD, PhD, Seiji Kojima, MD, PhD, Seishi Ogawa, MD, PhD, Mikkael A. Sekeres, MD, MS, Hideki Makishima, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD
   
   
4. 1897 - The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies (Poster)
   Swapna Thota, MD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, Aaron D. Viny, MD, MS, Bhumika J Patel, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD, MS, Hetty E. Carraway, MD, MBA, Torsten Haferlach, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD
   
   
5. 1935 - The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA) (Poster)
   Amer M. Zeidan, MBBS, MHS, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Cassie Zimmerman, MA, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Katrina Zell, Quiqing Wang, Steven D Gore, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD, PhD, Alan F. List, MD and Rami S Komrokji, MD
   
   
6. 2642 - Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression (Poster)
   Aaron T. Gerds, MD, MS, Betsy Dennison, MS, RN, Joan Latsko, DNP, CRNP, Alice Houk, MS, RN, Stephanie Chisolm, PhD, John M. Huber, MS, Richard M. Stone, MD, Jaroslaw P. Maciejewski, MD, PhD, Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD and Mikkael A. Sekeres, MD, MS
   
   
7. 3233 - Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS (Poster)
   Bartlomiej P Przychodzen, Hideki Makishima, MD, PhD, Brittney Dienes, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD, MBA, Swapna Thota, MD, Bhumika J Patel, MD, Mikkael A. Sekeres, MD, MS and Jaroslaw P. Maciejewski, MD, PhD
   
   
8. 3251 - An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion (Poster)
   Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, Lionel Ades, MD, PhD, Abderrahmane Laadem, MD, Bond Vo, PharmD, Thomas Prebet, MD, PhD, Aspasia Stamatoullas, MD, Thomas Boyd, MD, Jacques Delaunay, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD, MS, Odile Beyne-Rauzy, MD, PhD, Jun Zou, MS, Kenneth Attie, MD, Matthew L. Sherman, MD, Pierre Fenaux, MD, PhD and Alan F. List, MD
   
   
9. 3273 - Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA) (Poster)
   Aziz Nazha, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Cassie Zimmerman, MA, Elias Jabbour, MD, Molly D. Greenberg, BS, Sangmin Lee, MD, Alan F List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD, PhD and Rami S Komrokji, MD
   
   
10. 3275 - The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure (Poster)
    Aziz Nazha, MD, Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, Cassie Zimmerman, MA, Al Ali Najla, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Elias Jabbour, MD, Sangmin Lee, MD, Molly D. Greenberg, BS, Alan F List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD, PhD and Mikkael A. Sekeres, MD, MS
    
    
11. 4641 - Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium (Poster)
    Elias Jabbour, MD, Koji Sasaki, Mikkael A. Sekeres, MD, MS, Rami S Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Roboz J Gail, MD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Courtney D. DiNardo, MD, Xuemei Wang, PhD, Graciela Nogueras-Gonzalez, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD
    
    
12. 18 - Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid Leukemia (Oral Presentation)
    R. Coleman Lindsley, MD, PhD, Brenton G. Mar, MD, PhD, Emanuele Mazzola, PhD, Peter Grauman, Sarah Shareef, Daniel J. DeAngelo, MD,PhD, Donna S. Neuberg, ScD, Richard M. Stone, MD and Benjamin L. Ebert, MD, DPhil
    
    
13. 1892 - Reduced Protein Synthesis and p53 Activation in Late-Stage Erythroblasts Mediate the Erythroid Differentiation Defect in Mice with Ribosomal Protein S14 Haploinsufficiency (Poster)
    Rebekka K. Schneider, MD, Marie E. McConkey, PhD, Lisa P. Chu and Benjamin L. Ebert, MD PhD
    
    
14. 3567 - GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition (Poster)
    Akinori Yoda, PhD, Guillaume Adelmant, PhD, Jerome Tamburini, MD, PhD, Bjoern Chapuy, MD, PhD, Nobuaki Shindoh, PhD, Yuka Yoda, MPH, Oliver Weigert, MD, Nadja Kopp, MA, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Amanda L Christie, Kutlu G Elpek, Joseph Card, Kira Gritsman, MD, PhD, Jason Gotlib, MD, MS, Michael W. Deininger, Hideki Makishima, MD, PhD, Shannon Turley, PhD, Nathalie Javidi-Sharifi, Jaroslaw P. Maciejewski, MD, PhD, Scott J Rodig, MD, PhD, Jeffrey W. Tyner, Jarrod A Marto, PhD, David M. Weinstock, MD and Andrew A. Lane, MD, PhD
    
    
15. 528 - Aberrant Hedgehog Pathway Activity Marks Clinical MDS Progression and Accelerates Leukemic Transformation in Vivo (Oral Presentation)
    Lukasz P Gondek, MD, PhD, Yiting Lim, PhD, Hideki Makishima, MD, PhD, Qiuju Wang, MA, Jaroslaw P. Maciejewski, MD, PhD, FACP, Peter D Aplan, MD, Amy E. DeZern, MD, MHS and William Matsui, MD
    
    
16. 1922 - Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes) (Poster)
    Koji Sasaki, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Sherry Pierce, BSN, BA, Gautam Borthakur, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD
    
    
17. 3241 - Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes (Poster)
    Yue Wei, Monica Cabrero, MD, Yu Jia, Hong Zheng, Hui Yang, MD, PhD, Zhihong Fang, Zach Bohannan, Rui Chen, PhD, Hui Wang, PhD, Simona Colla, Xia Wang and Guillermo Garcia-Manero, MD
    
    
18. 4631 - Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications (Poster)
    Talha Badar, MBBS, FCPS, Philip A Thompson, MBBS, Binsah George, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge Cortes, MD, Marina Konopleva, MD, PhD, Tapan M. Kadia, MD, Zach Bohannan, Sherry Pierce, BSN, BA, Elias Jabbour, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Keyur P. Patel, MD, PhD, Raja Luthra, Victoria Sukholutsky and Guillermo Garcia Manero, MD
    
    
19. 4640 - Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) (Poster)
    Elias Jabbour, MD, Koji Sasaki, Naval Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MD, Tapan Kadia, MD, Darla Miller, Victoria Sukholutsky, Xuelin Huang, PhD, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD
    
    
20. 4658 - Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes (Poster)
    Keyur Patel, Mark Routbort, MD, PhD, Graciela Noguera-Gonzalez, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Zeev Estrov, MD, Naval G. Daver, MD, William G Wierda, MD, PhD, Nitin Jain, MD, Susan O'Brien, MD, Marina Konopleva, MD, PhD, Jorge Cortes, MD, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Carlos E. Bueso-Ramos, MD, PhD, Raja Luthra, Rajesh Singh, PhD, Sherry Pierce, BSN, BA, L. Jeffrey Medeiros, MD, Zachary Bohannan, Xuelin Huang, PhD and Guillermo Garcia-Manero, MD
    
    
21. 4663 - Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes (Poster)
    Yue Wei, Amit Verma, MD, Monica Cabrero, MD, Yu Jia, Hong Zheng, Zhihong Fang, Yiting Yu, PhD, Simona Colla, Zach Bohannan, Teresa V. Bowman, PhD, Jacqueline Boultwood, PhD and Guillermo Garcia-Manero, MD
    
    
22. 4664 - Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up (Poster)
    Monica Cabrero, MD, Elias Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan Kadia, MD, Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD
    
    
23. 4666 - Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study (Poster)
    Monica Cabrero, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Betul Oran, MD, Richard E. Champlin, Hagop M. Kantarjian, MD and Elias Jabbour, MD